Linezolid Shortage: What Providers and Prescribers Need to Know in 2026

As of 2026, linezolid injection remains on the ASHP active drug shortage list, with specific IV bag formulations from Pfizer and Hikma in limited supply. This shortage creates meaningful clinical challenges for infectious disease physicians, hospitalists, intensivists, and the discharge planning teams and home infusion pharmacies who depend on consistent linezolid availability for post-discharge OPAT programs.

This guide summarizes the clinical and operational implications of the shortage, reviews the evidence for alternatives, and provides practical stewardship guidance.

Current Shortage Scope: What Is and Is Not Available

The ASHP shortage (first created October 2024, updated October 2025) affects:

• Pfizer (Zyvox): 2 mg/mL 100 mL and 300 mL bags — limited supply, manufacturing delays cited
• Hikma: 2 mg/mL 300 mL bags — limited supply, reason not disclosed

Available manufacturers: Eugia US, Fresenius Kabi, Piramal Critical Care, Sandoz, Sun Pharma. Oral tablets (600 mg) and oral suspension (100 mg/5 mL) remain off the shortage list.

Clinical Indications Most Affected by the Shortage

Understanding which patient populations depend most on IV linezolid helps prioritize supply and identify where transitions are most feasible:

• VRE infections (E. faecium bacteremia, line infections): Linezolid is the only FDA-approved agent specifically for VRE, giving it unique status. For serious VRE infections in patients who cannot take oral agents, securing IV linezolid is highest priority.
• MRSA pneumonia (HAP/VAP): IDSA/ATS guidelines recommend vancomycin or linezolid for MRSA-associated HAP and VAP. Both are acceptable first-line options. Some data suggest better lung penetration with linezolid, making the shortage particularly relevant in ICU settings.
• OPAT patients on step-down IV linezolid: Post-discharge patients receiving IV linezolid via OPAT programs are acutely vulnerable to supply disruptions. Early IV-to-oral transitions where clinically appropriate are a priority mitigation strategy.

IV-to-Oral Transition: Clinical Considerations

Oral linezolid (600 mg tablet) has approximately 100% bioavailability, meaning serum concentrations are essentially equivalent to the IV formulation. For clinically stable patients who can take oral medications and have a functioning GI tract, transition to oral linezolid is pharmacologically justified and should be considered proactively during the current shortage.

Clinical criteria for IV-to-oral switch:

• Patient is clinically stable and afebrile or improving
• Able to tolerate oral intake without GI malabsorption concerns
• No concerns about GI motility (ileus, short bowel syndrome, severe diarrhea)
• Infection is in a site accessible to oral distribution (not endocarditis, meningitis, or other deep-seated infections where IV is strongly preferred)

Alternative Therapy Considerations by Indication

VRE infections: High-dose daptomycin (≥8 mg/kg daily) is widely used off-label for VRE bacteremia when linezolid is unavailable or not tolerated. Evidence suggests that daptomycin achieves comparable outcomes to linezolid when pharmacokinetic/pharmacodynamic targets (fAUC/MIC >75) are reached. Early ID consultation is essential.

MRSA pneumonia: Vancomycin remains the primary alternative. Monitor AUC-guided dosing (target AUC/MIC 400–600). Telavancin is a second-line option with FDA approval for MRSA HAP/VAP but carries nephrotoxicity risk.

MRSA SSTIs: Tedizolid (Sivextro) is a direct oxazolidinone alternative for ABSSSIs with once-daily dosing. Daptomycin or vancomycin are also appropriate alternatives for complicated SSTIs.

Safety Monitoring Reminders During the Shortage

When prescribing or continuing linezolid, reinforce standard monitoring protocols:

• Weekly CBC monitoring for treatment courses >14 days (myelosuppression risk)
• Serotonin drug interaction review — particularly critical in patients on SSRIs, SNRIs, TCAs, triptans, or opioids
• Limit therapy to 28 days maximum when possible (peripheral and optic neuropathy risk with prolonged use)
• Monitor blood glucose in diabetic patients receiving insulin or oral hypoglycemics (hypoglycemia risk)

For help connecting your patients to pharmacies with linezolid in stock, visit medfinder for providers. medfinder calls pharmacies near your patients to confirm linezolid availability and texts results directly to patients, saving significant time for your care team.